Treatment With Cladribine Selects IFNγ+IL17+ T Cells in RRMS Patients - An In Vitro Study.
Dobreanu M, Manu DR, Mănescu IB, Gabor MR, Huţanu A, Bărcuţean L, Bălaşa R.
Dobreanu M, et al.
Front Immunol. 2021 Dec 14;12:743010. doi: 10.3389/fimmu.2021.743010. eCollection 2021.
Front Immunol. 2021.
PMID: 34970256
Free PMC article.
Ex vivo to in vitro phenotype shifts included: decreased CD3+CCR6+ and CD3+CD161+ in all subjects and increased CD3+CXCR3+ in RRMS patients only; Th17.1 showed increased proliferation vs Th17 in all subjects; CD3+IL17+ and CD3+IFNgamma+IL17+ continued to proliferate till d …
Ex vivo to in vitro phenotype shifts included: decreased CD3+CCR6+ and CD3+CD161+ in all subjects and increased CD3+CXCR3+ in RRMS patients …